AgomAb Therapeutics NV Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2019	FY 2018
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Cost of Revenue	-	-	-	-	2.89	0.39
Gross Profit	-	-	-	-	-2.89	-0.39
Selling, General & Admin	11.09	10.13	6.1	4.51	0.2	-
Research & Development	45.74	39.31	26.31	19.42	-	-
Other Operating Expenses	-2.27	-1.42	-1.22	-1.3	0	-
Operating Expenses	54.56	48.02	31.19	22.63	0.2	-
Operating Income	-54.56	-48.02	-31.19	-22.63	-3.09	-0.39
Interest Expense	-0.04	-0.07	-0.03	-0.05	-0.04	-0
Interest & Investment Income	1.5	1.22	0.25	0.07	0.03	-
Currency Exchange Gain (Loss)	-0.23	-0.23	0.01	-0.09	-	-
Other Non Operating Income (Expenses)	-3.54	0.84	18.96	11.89	-	-
Pretax Income	-56.87	-46.26	-12.01	-10.81	-3.1	-0.39
Income Tax Expense	0	0	-0.62	-2.66	-0.05	-
Net Income	-56.88	-46.27	-11.39	-8.14	-3.05	-0.39
Preferred Dividends & Other Adjustments	15.39	11.58	7.89	5.42	-	-
Net Income to Common	-72.27	-57.85	-19.28	-13.56	-3.05	-0.39
Shares Outstanding (Basic)	0	0	0	0	-	-
Shares Outstanding (Diluted)	0	0	0	0	-	-
EPS (Basic)	-2890.60	-2314.04	-771.28	-542.56	-	-
EPS (Diluted)	-2890.60	-2314.04	-771.28	-542.56	-	-
Free Cash Flow	-51.37	-47.5	-24.59	-18.97	-	-
Free Cash Flow Per Share	-2054.80	-1900.12	-983.68	-758.68	-	-
EBITDA	-54.43	-47.97	-31.09	-22.61	-	-
D&A For EBITDA	0.13	0.06	0.1	0.02	-	-
EBIT	-54.56	-48.02	-31.19	-22.63	-3.09	-0.39

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q